Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:AMGN
- CUSIP: 03116210
- Web: www.amgen.com
Capitalization:- Market Cap: $135.95302 billion
- Outstanding Shares: 729,674,000
Average Prices:- 50 Day Moving Avg: $175.99
- 200 Day Moving Avg: $169.31
- 52 Week Range: $133.64 - $191.10
P/E:- Trailing P/E Ratio: 17.14
- Foreward P/E Ratio: 14.79
- P/E Growth: 3.63
Sales & Book Value:- Annual Revenue: $23.05 billion
- Price / Sales: 5.96
- Book Value: $43.41 per share
- Price / Book: 4.33
Dividend:- Annual Dividend: $4.60
- Dividend Yield: 2.5%
Profitability:- EBIDTA: $12.36 billion
- Net Margins: 35.46%
- Return on Equity: 29.85%
- Return on Assets: 11.72%
Debt:- Debt-to-Equity Ratio: 1.06%
- Current Ratio: 6.20%
- Quick Ratio: 5.82%
Misc:- Average Volume: 2.81 million shs.
- Beta: 1.35
- Short Ratio: 2.81
Frequently Asked Questions for Amgen (NASDAQ:AMGN)
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Friday, July 28th. Investors of record on Thursday, August 17th will be given a dividend of $1.15 per share on Friday, September 8th. This represents a $4.60 annualized dividend and a yield of 2.44%. The ex-dividend date is Tuesday, August 15th. View Amgen's Dividend History.
How were Amgen's earnings last quarter?
Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings data on Tuesday, July, 25th. The company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business's revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.84 earnings per share. View Amgen's Earnings History.
When will Amgen make its next earnings announcement?
Where is Amgen's stock going? Where will Amgen's stock price be in 2017?
21 brokerages have issued twelve-month price objectives for Amgen's stock. Their forecasts range from $161.00 to $209.00. On average, they expect Amgen's stock price to reach $186.83 in the next year. View Analyst Ratings for Amgen.
What are analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. Cann analysts commented, "Amgen announced today positive results from a new Repatha (evolocumab) analysis of cardiovascular outcomes study (FOURIER) that showed a statistically significant relationship between lower achieved low-density lipoprotein cholesterol (LDL-C) levels and lower cardiovascular event rates in patients with established atherosclerotic cardiovascular disease. Importantly, there was no evidence of a leveling off of effect and no new safety concerns were identified in this analysis." (8/28/2017)
- 2. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
- 3. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), BIOVERATIV INC (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), AveXis (AVXS), Sarepta Therapeutics (SRPT) and Axovant Sciences Ltd (AXON).
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
- David W. Meline, Executive Vice President, Chief Financial Officer
- Sean E. Harper, Executive Vice President - Research and Development
- Anthony C. Hooper, Executive Vice President - Global Commercial Operations
- Brian M. McNamee, Executive Vice President - Full Potential Initiatives
- Esteban Santos, Executive Vice President, Operations
- Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
- Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
- Lori A. Johnston, Senior Vice President
- David A. Piacquad, Senior Vice President - Business Development
Who owns Amgen stock?
Amgen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (7.81%), Capital Research Global Investors (7.37%), Vanguard Group Inc. (7.15%), BlackRock Inc. (6.78%), State Street Corp (4.53%) and Northern Trust Corp (1.27%). Company insiders that own Amgen stock include Annette Louise Such, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.
Who sold Amgen stock? Who is selling Amgen stock?
Amgen's stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, AJO LP, Standard Life Investments LTD, State Street Corp, FIL Ltd, American Century Companies Inc., Bank of New York Mellon Corp and Bank of Nova Scotia. View Insider Buying and Selling for Amgen.
Who bought Amgen stock? Who is buying Amgen stock?
Amgen's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Renaissance Technologies LLC, BlackRock Inc., Nordea Investment Management AB, Parametric Portfolio Associates LLC, Ameriprise Financial Inc. and Canada Pension Plan Investment Board. View Insider Buying and Selling for Amgen.
How do I buy Amgen stock?
Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of Amgen stock can currently be purchased for approximately $188.17.
MarketBeat Community Rating for Amgen (NASDAQ AMGN)MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Amgen (NASDAQ:AMGN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 11 Hold Ratings, 9 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.52) |
| Consensus Price Target: | $186.83 (0.71% downside) |
Analysts' Ratings History for Amgen (NASDAQ:AMGN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/14/2017 | Royal Bank Of Canada | Initiated Coverage | Sector Perform -> Sector Perform | $192.00 | High |  |
| 9/7/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | $203.00 | Low | |
| 8/28/2017 | Cann | Reiterated Rating | Buy | | Low | |
| 8/21/2017 | Mizuho | Reiterated Rating | Buy | $195.00 -> $183.00 | Low | |
| 7/27/2017 | Argus | Boost Price Target | Buy | $180.00 -> $195.00 | Low | |
| 7/26/2017 | Deutsche Bank AG | Reiterated Rating | Hold | $172.00 -> $174.00 | Low | |
| 7/26/2017 | BMO Capital Markets | Downgrade | Outperform -> Market Perform | | Low | |
| 7/22/2017 | Cowen and Company | Reiterated Rating | Outperform | $209.00 | Low | |
| 7/17/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $195.00 | Low | |
| 7/14/2017 | Credit Suisse Group | Set Price Target | Hold | $177.00 | Low | |
| 7/10/2017 | Morgan Stanley | Reiterated Rating | Overweight | | Low | |
| 6/26/2017 | William Blair | Reiterated Rating | Market Perform | | Low | |
| 6/22/2017 | Leerink Swann | Reiterated Rating | Market Perform | $161.00 | Low | |
| 6/8/2017 | Sanford C. Bernstein | Set Price Target | Hold | $164.00 | Medium | |
| 4/28/2017 | Robert W. Baird | Reiterated Rating | Neutral | $165.00 | Low | |
| 3/20/2017 | Goldman Sachs Group, Inc. (The) | Lower Price Target | Conviction-Buy | $208.00 -> $202.00 | Low | |
| 3/14/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $193.00 | Low | |
| 2/1/2017 | Bank of America Corporation | Upgrade | Neutral -> Buy | $156.68 -> $192.00 | N/A | |
| 12/13/2016 | Chardan Capital | Upgrade | Sell -> Neutral | | N/A | |
| 9/28/2016 | Citigroup Inc. | Lower Price Target | Neutral | $175.00 -> $172.00 | N/A | |
| 9/28/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | | N/A | |
| 8/26/2016 | Gabelli | Initiated Coverage | Hold | | N/A | |
| 7/28/2016 | Barclays PLC | Reiterated Rating | Equal Weight | $185.00 | N/A | |
| 2/23/2016 | BTIG Research | Reiterated Rating | Sell | $135.00 | N/A | |
| 1/22/2016 | Wells Fargo & Company | Reiterated Rating | Hold | | N/A | |
| 12/18/2015 | Atlantic Securities | Initiated Coverage | Overweight | $202.00 | N/A | |
| 9/22/2015 | Nomura | Reiterated Rating | Buy | $190.00 -> $191.00 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Amgen (NASDAQ:AMGN)Earnings History by Quarter for Amgen (NASDAQ AMGN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | $3.11 | | | | | N/A | |
| 7/25/2017 | Q2 2017 | $3.11 | $3.27 | $5.67 billion | $5.81 billion | View | N/A | |
| 4/26/2017 | Q1 2017 | $3.00 | $3.15 | $5.60 billion | $5.46 billion | View | N/A | |
| 2/2/2017 | Q416 | $2.79 | $2.89 | $5.75 billion | $5.97 billion | View | Listen | |
| 10/27/2016 | Q316 | $2.79 | $3.02 | $5.73 billion | $5.81 billion | View | Listen | |
| 7/27/2016 | Q216 | $2.74 | $2.84 | $5.58 billion | $5.69 billion | View | Listen | |
| 4/28/2016 | Q116 | $2.60 | $2.90 | $5.32 billion | $5.53 billion | View | Listen | |
| 1/28/2016 | Q415 | $2.29 | $2.61 | $5.53 billion | $5.54 billion | View | Listen | |
| 10/28/2015 | Q315 | $2.38 | $2.72 | $5.32 billion | $5.72 billion | View | Listen | |
| 7/30/2015 | Q215 | $2.43 | $2.57 | $5.32 billion | $5.37 billion | View | Listen | |
| 4/21/2015 | Q115 | $2.07 | $2.48 | $4.91 billion | $5.03 billion | View | Listen | |
| 1/27/2015 | Q414 | $2.05 | $2.16 | $5.20 billion | $5.33 billion | View | Listen | |
| 10/27/2014 | Q314 | $2.11 | $2.30 | $4.95 billion | $5.03 billion | View | Listen | |
| 7/29/2014 | Q214 | $2.07 | $2.37 | $4.90 billion | $5.18 billion | View | Listen | |
| 4/22/2014 | Q114 | $1.94 | $1.87 | $4.76 billion | $4.52 billion | View | Listen | |
| 1/28/2014 | Q413 | $1.69 | $1.82 | $4.81 billion | $5.01 billion | View | Listen | |
| 10/22/2013 | Q313 | $1.78 | $1.94 | $4.60 billion | $4.75 billion | View | Listen | |
| 7/30/2013 | Q2 2013 | $1.74 | $1.89 | $4.49 billion | $4.68 billion | View | Listen | |
| 4/23/2013 | Q1 2013 | $1.84 | $1.96 | $4.37 billion | $4.24 billion | View | N/A | |
| 1/23/2013 | Q4 2012 | $1.42 | $1.40 | $4.37 billion | $4.42 billion | View | Listen | |
| 10/23/2012 | | $1.47 | $1.67 | | | View | N/A | |
| 7/26/2012 | | $1.54 | $1.83 | | | View | N/A | |
| 1/26/2012 | | $1.22 | $1.21 | | | View | N/A | |
| 10/24/2011 | | $1.29 | $1.40 | | | View | N/A | |
| 7/29/2011 | | $1.29 | $1.37 | | | View | N/A | |
| 4/20/2011 | | $1.29 | $1.34 | | | View | N/A | |
| 1/24/2011 | | $1.11 | $1.17 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Amgen (NASDAQ:AMGN)2017 EPS Consensus Estimate: $12.28
2018 EPS Consensus Estimate: $12.67
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $3.04 | $3.17 | $3.09 |
| Q2 2017 | 3 | $3.05 | $3.12 | $3.09 |
| Q3 2017 | 3 | $3.01 | $3.17 | $3.11 |
| Q4 2017 | 3 | $2.97 | $2.99 | $2.98 |
| Q1 2018 | 1 | $3.29 | $3.29 | $3.29 |
| Q2 2018 | 1 | $3.18 | $3.18 | $3.18 |
| Q3 2018 | 1 | $3.10 | $3.10 | $3.10 |
| Q4 2018 | 1 | $3.10 | $3.10 | $3.10 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Amgen (NASDAQ:AMGN)| Most Recent Dividend: | 9/8/2017 |
| Annual Dividend: | $4.60 |
| Dividend Yield: | 2.44% |
| Dividend Growth: | 28.60% (3 Year Average) |
| Payout Ratio: | 41.93% (Trailing 12 Months of Earnings)
36.86% (Based on This Year's Estimates)
36.16% (Based on Next Year's Estimates)
|
| Track Record: | 6 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Amgen (NASDAQ AMGN)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/28/2017 | quarterly | $1.15 | 2.64% | 8/15/2017 | 8/17/2017 | 9/8/2017 |
| 3/7/2017 | quarterly | $1.15 | 2.59% | 5/15/2017 | 5/17/2017 | 6/8/2017 |
| 12/20/2016 | quarterly | $1.15 | 3.15% | 2/13/2017 | 2/15/2017 | 3/8/2017 |
| 10/14/2016 | quarterly | $1.00 | 2.46% | 11/14/2016 | 11/16/2016 | 12/8/2016 |
| 7/22/2016 | quarterly | $1.00 | 2.4% | 8/15/2016 | 8/17/2016 | 9/8/2016 |
| 3/2/2016 | quarterly | $1.00 | 2.74% | 5/13/2016 | 5/17/2016 | 6/8/2016 |
| 12/15/2015 | quarterly | $1.00 | 2.43% | 2/11/2016 | 2/16/2016 | 3/8/2016 |
| 10/14/2015 | quarterly | $0.79 | 2.07% | 11/12/2015 | 11/16/2015 | 12/7/2015 |
| 7/28/2015 | quarterly | $0.79 | 1.84% | 8/13/2015 | 8/17/2015 | 9/8/2015 |
| 3/4/2015 | quarterly | $0.79 | 1.98% | 5/12/2015 | 5/14/2015 | 6/5/2015 |
| 12/17/2014 | quarterly | $0.79 | 1.88% | 2/10/2015 | 2/12/2015 | 3/6/2015 |
| 10/17/2014 | quarterly | $0.61 | 1.77% | 11/10/2014 | 11/13/2014 | 12/5/2014 |
| 7/25/2014 | quarterly | $0.61 | 1.99% | 8/12/2014 | 8/14/2014 | 9/5/2014 |
| 3/5/2014 | quarterly | $0.61 | 1.96% | 5/13/2014 | 5/15/2014 | 6/6/2014 |
| 12/13/2013 | quarterly | $0.61 | 2.18% | 2/11/2014 | 2/13/2014 | 3/7/2014 |
| 10/16/2013 | quarterly | $0.47 | 1.62% | 11/12/2013 | 11/14/2013 | 12/6/2013 |
| 7/26/2013 | quarterly | $0.47 | 1.72% | 8/14/2013 | 8/16/2013 | 9/6/2013 |
| 3/6/2013 | quarterly | $0.47 | 2.02% | 5/14/2013 | 5/16/2013 | 6/7/2013 |
| 12/13/2012 | quarterly | $0.47 | 2.11% | 2/11/2013 | 2/13/2013 | 3/7/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Amgen (NASDAQ:AMGN)Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 78.09%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/24/2017 | Cynthia M Patton | SVP | Sell | 2,922 | $154.40 | $451,156.80 | |
| 8/2/2016 | Annette Louise Such | VP | Sell | 3,000 | $174.59 | $523,770.00 | |
| 5/4/2016 | Madhavan Balachandran | EVP | Sell | 30,000 | $154.12 | $4,623,600.00 | |
| 4/29/2016 | David Baltimore | Director | Sell | 3,312 | $157.21 | $520,679.52 | |
| 4/29/2016 | Sean E Harper | EVP | Sell | 21,875 | $157.99 | $3,456,031.25 | |
| 8/31/2015 | Carbonnel Francois De | Director | Sell | 5,000 | $153.84 | $769,200.00 | |
| 8/19/2015 | Fred Hassan | Director | Buy | 3,010 | $166.63 | $501,556.30 | |
| 6/2/2015 | Cynthia M Patton | SVP | Sell | 4,530 | $157.06 | $711,481.80 | |
| 4/23/2015 | Stuart A Tross | SVP | Sell | 3,012 | $169.31 | $509,961.72 | |
| 4/22/2015 | Sean E Harper | EVP | Sell | 28,000 | $171.58 | $4,804,240.00 | |
| 3/3/2015 | Stuart A Tross | SVP | Sell | 4,415 | $157.74 | $696,422.10 | |
| 3/2/2015 | David Baltimore | Director | Sell | 3,647 | $158.76 | $578,997.72 | |
| 2/11/2015 | Robert A Bradway | CEO | Sell | 22,000 | $152.69 | $3,359,180.00 | |
| 2/5/2015 | Frank C Herringer | Director | Buy | 3,000 | $152.29 | $456,870.00 | |
| 12/3/2014 | Carbonnel Francois De | Director | Sell | 3,000 | $168.01 | $504,030.00 | |
| 8/5/2014 | Cynthia M Patton | SVP | Sell | 2,644 | $127.97 | $338,352.68 | |
| 8/5/2014 | Sean E Harper | EVP | Sell | 14,000 | $127.29 | $1,782,060.00 | |
| 5/21/2014 | Thomas J.W. Dittrich | CAO | Sell | 4,130 | $112.83 | $465,987.90 | |
| 4/28/2014 | A Kelly Michael | CFO | Sell | 2,065 | $110.45 | $228,079.25 | |
| 3/6/2014 | Carbonnel Francois De | Director | Sell | 1,000 | $126.69 | $126,690.00 | |
| 9/4/2013 | Madhavan Balachandran | EVP | Sell | 18,000 | $112.76 | $2,029,680.00 | |
| 8/28/2013 | David Baltimore | Director | Sell | 4,582 | $109.66 | $502,462.12 | |
| 5/22/2013 | Thomas J.W. Dittrich | CAO | Sell | 6,130 | $104.78 | $642,301.40 | |
| 5/21/2013 | Madhavan Balachandran | EVP | Sell | 6,000 | $103.28 | $619,680.00 | |
| 5/17/2013 | Rebecca M Henderson | Director | Sell | 8,421 | $105.72 | $890,268.12 | |
| 5/16/2013 | Cynthia M Patton | SVP | Sell | 3,544 | $105.01 | $372,155.44 | |
| 5/14/2013 | Judith C Pelham | Director | Sell | 25,000 | $108.25 | $2,706,250.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Amgen (NASDAQ:AMGN)
Latest Headlines for Amgen (NASDAQ:AMGN)
| Source: |
|
| Date | Headline |
|---|
 | AMGEN (AMGN) ALERT: Johnson Fistel Announces Investigation of Amgen Inc.; Investors that Bought Before March 17 ... - PR Newswire (press release)
www.prnewswire.com - September 20 at 8:59 PM |
 | AMGEN (AMGN) ALERT: Johnson Fistel Announces Investigation of Amgen Inc.; Investors that Bought Before March 17, 2017, Encouraged to Contact the Firm
finance.yahoo.com - September 20 at 8:59 PM |
| deCODE Study Reveals an Ancient Achilles Heel in the Human Genome
finance.yahoo.com - September 20 at 3:58 PM |
 | Is Amgen (AMGN) a Great Stock for Value Investors? - Nasdaq.com - Nasdaq
www.nasdaq.com - September 19 at 3:49 PM |
 | Amgen and Allergan: Avastin Biosimilar Approval Part 2 - Seeking Alpha
seekingalpha.com - September 19 at 3:49 PM |
| FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy
finance.yahoo.com - September 18 at 4:11 PM |
| We're not chasing electric utilities: Heartland Financial...
finance.yahoo.com - September 18 at 4:11 PM |
| Amgen Could Rally Higher On This Breakout - Seeking Alpha
seekingalpha.com - September 15 at 9:11 PM |
| New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes
finance.yahoo.com - September 15 at 4:08 PM |
| Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
finance.yahoo.com - September 15 at 4:08 PM |
 | A Biosimilar Cure for Sky-High Cancer Drug Prices
www.fool.com - September 14 at 9:49 PM |
 | Amgen challenge to Genentech $6 billion cancer drug OK'd by FDA - San Francisco Business Times
www.bizjournals.com - September 14 at 9:26 PM |
| Amgen Needs To Get Lucky With Repatha - Seeking Alpha
seekingalpha.com - September 14 at 9:26 PM |
| Biosimilar 2017 Progress Report: Stocks in Focus
finance.yahoo.com - September 14 at 9:26 PM |
| FDA Approves First 'Biosimilar' for Cancer Treatment
finance.yahoo.com - September 14 at 9:26 PM |
 | Amgen Inc. (AMGN) Receives New Coverage from Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 5:26 PM |
| Noteworthy Thursday Option Activity: AMGN, RCL, CVX
www.nasdaq.com - September 14 at 4:20 PM |
| The FDA just approved the first direct competitor to a billion-dollar cancer drug
finance.yahoo.com - September 14 at 4:20 PM |
| UAB makes headway with new osteoporosis drug
finance.yahoo.com - September 14 at 4:20 PM |
| U.S. FDA approves biosimilar version of cancer drug Avastin
finance.yahoo.com - September 14 at 4:20 PM |
| Amgen, Inc. : AMGN-US: Dividend Analysis : August 17th, 2017 (record date) : By the numbers : September 14, 2017
finance.yahoo.com - September 14 at 4:20 PM |
| Amgen challenge to Genentech $6 billion cancer drug OK'd by FDA
finance.yahoo.com - September 14 at 4:20 PM |
| Amgen Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - September 13 at 9:59 PM |
| 5 Ways To Play 2017’s Biotech Boom
finance.yahoo.com - September 13 at 9:58 PM |
 | Supercharge Your Portfolio With Amgen, Inc. (AMGN) Stock - Investorplace.com
investorplace.com - September 12 at 9:06 PM |
 | Amgen Stock Breaks Out From Resistance
www.investopedia.com - September 12 at 4:03 PM |
| 3 Things Amgen Inc.'s Management Just Said That You'll Want to Know
www.fool.com - September 12 at 4:03 PM |
| What Does Amgen Inc’s (AMGN) Share Price Indicate?
finance.yahoo.com - September 12 at 4:03 PM |
| Amgen Builds on a Breakout
finance.yahoo.com - September 12 at 4:03 PM |
| 3 Things Amgen Inc.'s Management Just Said That You'll Want to Know
finance.yahoo.com - September 12 at 4:03 PM |
| Supercharge Your Portfolio With Amgen, Inc. (AMGN) Stock
investorplace.com - September 12 at 11:48 AM |
 | Carter Worth And Mike Khouw's Amgen Trade - Benzinga
www.benzinga.com - September 12 at 2:46 AM |
| OncoSec Seeks Accelerated Approval to Treat Melanoma
finance.yahoo.com - September 11 at 9:46 PM |
| Interesting AMGN Put And Call Options For January 2020
www.nasdaq.com - September 11 at 4:45 PM |
| What’s Gilead Sciences’ Valuation?
finance.yahoo.com - September 11 at 4:45 PM |
| EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine
finance.yahoo.com - September 11 at 4:45 PM |
| Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
finance.yahoo.com - September 11 at 4:45 PM |
 | The ‘greatest stock of all time’ just came back to life: Technician
www.cnbc.com - September 11 at 1:16 PM |
| Zacks: Brokerages Expect Amgen Inc. (AMGN) Will Post Quarterly Sales of $5.73 Billion
www.americanbankingnews.com - September 10 at 9:20 AM |
| Amgen Inc. (AMGN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 9 at 8:38 PM |
| Amgen Highlights The Latest EVENITY™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting
finance.yahoo.com - September 8 at 4:13 PM |
| New AstraZeneca, Amgen drug looks strong rival in severe asthma
finance.yahoo.com - September 7 at 8:55 PM |
| AstraZeneca's COPD Candidate Duaklir Reports Positive Data
finance.yahoo.com - September 7 at 8:55 PM |
| Amgen To Present At The Morgan Stanley Global Healthcare Conference
finance.yahoo.com - September 7 at 8:55 PM |
| New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies
finance.yahoo.com - September 7 at 8:55 PM |
| Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise - Nasdaq
www.nasdaq.com - September 7 at 3:49 PM |
| Noteworthy Thursday Option Activity: AMGN, CVX, CMCSA - Nasdaq
www.nasdaq.com - September 7 at 3:49 PM |
| Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise
finance.yahoo.com - September 7 at 3:49 PM |
| Oppenheimer Holdings, Inc. Reaffirms "Buy" Rating for Amgen Inc. (AMGN)
www.americanbankingnews.com - September 7 at 3:26 PM |
| New AstraZeneca, Amgen biotech drug offers broad asthma relief
finance.yahoo.com - September 6 at 8:48 PM |
Amgen (AMGN) Chart for Thursday, September, 21, 2017
